Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer's disease mild cognitive impairment progression at a 6-month follow-up

Babiloni C., Jakhar D., Tucci F., Del Percio C., Lopez S., Soricelli A., ...More

Neurobiology of Aging, vol.137, pp.19-37, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 137
  • Publication Date: 2024
  • Doi Number: 10.1016/j.neurobiolaging.2024.01.013
  • Journal Name: Neurobiology of Aging
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Abstracts in Social Gerontology, BIOSIS, CAB Abstracts, Psycinfo, Veterinary Science Database
  • Page Numbers: pp.19-37
  • Keywords: Alzheimer's disease progression, Exact Low-resolution Brain Electromagnetic Source Tomography (eLORETA), Mild cognitive impairment due to Alzheimer's disease (ADMCI), Resting state electroencephalographic (rsEEG) rhythms
  • Istanbul Medipol University Affiliated: Yes


Are posterior resting-state electroencephalographic (rsEEG) alpha rhythms sensitive to the Alzheimer's disease mild cognitive impairment (ADMCI) progression at a 6-month follow-up? Clinical, cerebrospinal, neuroimaging, and rsEEG datasets in 52 ADMCI and 60 Healthy old seniors (equivalent groups for demographic features) were available from an international archive ( The ADMCI patients were arbitrarily divided into two groups: REACTIVE and UNREACTIVE, based on the reduction (reactivity) in the posterior rsEEG alpha eLORETA source activities from the eyes-closed to eyes-open condition at ≥ −10% and −10%, respectively. 75% of the ADMCI patients were REACTIVE. Compared to the UNREACTIVE group, the REACTIVE group showed (1) less abnormal posterior rsEEG source activity during the eyes-closed condition and (2) a decrease in that activity at the 6-month follow-up. These effects could not be explained by neuroimaging and neuropsychological biomarkers of AD. Such a biomarker might reflect abnormalities in cortical arousal in quiet wakefulness to be used for clinical studies in ADMCI patients using 6-month follow-ups.